drugset / Trial / NCT00380250

Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

NCT00380250

Phase 3 Completed 590 enrolled Sucampo Pharma Americas, LLC Takeda · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose of this study is to evaluate the efficacy and safety of administration of lubiprostone in patients with irritable bowel syndrome with constipation.

Timeline

Start
2005-05
Primary completion
Completion
2006-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Lubiprostone Small molecule 8 ug